{"DataElement":{"publicId":"2695747","version":"1","preferredName":"Carboplatin Agent Substitution Cisplatin First Administered Reason","preferredDefinition":"the reason the initial administration of carboplatin (an anticancer drug that belongs to the family of drugs called platinum compounds) was required as a substutition or replacement for cisplatin, an anticancer drug that belongs to the family of drugs called platinum compounds.","longName":"CA_AG_SU_CI_F_AD_RSN","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2695744","version":"1","preferredName":"Carboplatin Agent Substitution Cisplatin First Administered","preferredDefinition":"information related to initial administration of carboplatin (an anticancer drug that belongs to the family of drugs called platinum compounds) as a substutition or replacement for cisplatin, an anticancer drug that belongs to the family of drugs called platinum compounds.","longName":"CAR_AGT_SUB_CI_F_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2241605","version":"1","preferredName":"Carboplatin Agent","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04):An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1282:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-222A-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-07-08","modifiedBy":"ONEDATA","dateModified":"2005-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2695742","version":"1","preferredName":"Substitution Cisplatin First Administered","preferredDefinition":"The act of putting one thing or person in the place of another.:An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04):Preceding all others in time or space or degree.:Given.","longName":"C54071:C376:C25509:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Substitution","conceptCode":"C54071","definition":"The act of putting one thing or person in the place of another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"First","conceptCode":"C25509","definition":"Preceding all others in time or space or degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3ED72C13-6F94-060E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"ONEDATA","dateModified":"2007-11-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3ED72C13-6FA5-060E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2695746","version":"1","preferredName":"Agent Substitution Reason","preferredDefinition":"the explanation of the cause or action that required an agent to be substituted.","longName":"AGT_SUB_RSN","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Grade >=2 sensory or motor neuropathy for >1 week","valueDescription":"Grade >=2 sensory or motor neuropathy for >1 week","ValueMeaning":{"publicId":"2695749","version":"1","preferredName":"Grade >=2 sensory or motor neuropathy for >1 week","longName":"2695749","preferredDefinition":"Grade >=2 sensory or motor neuropathy for >1 week","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3ED76B7C-0AC8-09FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3ED76E12-AE8B-0813-E044-0003BA3F9857","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"ONEDATA","dateModified":"2007-11-13","deletedIndicator":"No"},{"value":"Nephrotoxicity","valueDescription":"Nephrotoxicity","ValueMeaning":{"publicId":"2695748","version":"1","preferredName":"Nephrotoxicity","longName":"2695748","preferredDefinition":"the poisonous effect of some substances, both toxic chemicals and medication, on the kidney.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3ED7589D-ECC1-08BA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3ED76E12-AE9D-0813-E044-0003BA3F9857","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"ONEDATA","dateModified":"2007-11-13","deletedIndicator":"No"},{"value":"Grade 2 persistent ototoxicity","valueDescription":"Grade 2 persistent ototoxicity","ValueMeaning":{"publicId":"2695750","version":"1","preferredName":"Grade 2 persistent ototoxicity","longName":"2695750","preferredDefinition":"Grade 2 persistent ototoxicity","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3ED76B7C-0AD8-09FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3ED76E12-AEAF-0813-E044-0003BA3F9857","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"ONEDATA","dateModified":"2007-11-13","deletedIndicator":"No"},{"value":"Grade 4 nausea and vomiting attributed to cisplatin despite antiemetics","valueDescription":"Grade 4 nausea and vomiting attributed to cisplatin despite antiemetics","ValueMeaning":{"publicId":"2695751","version":"1","preferredName":"Grade 4 nausea and vomiting attributed to cisplatin despite antiemetics","longName":"2695751","preferredDefinition":"Grade 4 nausea and vomiting attributed to cisplatin despite antiemetics","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3ED75B79-A588-0811-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3ED76E12-AEC1-0813-E044-0003BA3F9857","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"ONEDATA","dateModified":"2007-11-13","deletedIndicator":"No"},{"value":"Nephrotoxicity - see sections 5.5.1.5. and 5.5.3.4. of the protocol for details","valueDescription":"Nephrotoxicity","ValueMeaning":{"publicId":"2695748","version":"1","preferredName":"Nephrotoxicity","longName":"2695748","preferredDefinition":"the poisonous effect of some substances, both toxic chemicals and medication, on the kidney.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3ED7589D-ECC1-08BA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AE1AFBC1-CE82-4A0C-E040-BB89AD434199","beginDate":"2007-11-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-29","modifiedBy":"ONEDATA","dateModified":"2011-09-29","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2991873","version":"1","preferredName":"Other","longName":"2991873","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7DC8B94A-9F2D-1457-E040-BB89AD430D33","latestVersionIndicator":"Yes","beginDate":"2010-01-22","endDate":null,"createdBy":"AHMEDS","dateCreated":"2010-01-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Concept annotation added for UPitt/TCGA.  WZhang, 02/23/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D40F4A4-F1F9-DA31-E050-BB89AD432147","beginDate":"2015-01-22","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-22","modifiedBy":"ONEDATA","dateModified":"2015-01-22","deletedIndicator":"No"},{"value":"Ototoxicity","valueDescription":"Ototoxicity","ValueMeaning":{"publicId":"2571852","version":"1","preferredName":"Ototoxicity","longName":"2571852v1.00","preferredDefinition":"Damage to the inner ear as a result of exposure to drugs or chemicals.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ototoxicity","conceptCode":"C66929","definition":"Damage to the inner ear as a result of exposure to drugs or chemicals.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E5B9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-09-13","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D40F4A4-F203-DA31-E050-BB89AD432147","beginDate":"2015-01-22","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-22","modifiedBy":"ONEDATA","dateModified":"2015-01-22","deletedIndicator":"No"},{"value":"Neurotoxicity","valueDescription":"Neurotoxicity","ValueMeaning":{"publicId":"2580731","version":"1","preferredName":"Neurotoxicity","longName":"2580731v1.00","preferredDefinition":"A group of neurologic disorders caused by damage to the nervous system following exposure to pharmacologic, biologic, and chemical agents. Examples of neurotoxins include chemotherapy agents, radiation treatment, heavy metals, pesticides, and food additives.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurotoxicity Syndrome","conceptCode":"C27961","definition":"A group of neurologic disorders caused by damage to the nervous system following exposure to pharmacologic, biologic, and chemical agents. Examples of neurotoxins include chemotherapy agents, radiation treatment, heavy metals, pesticides, and food additives.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0868-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-09-01","modifiedBy":"KUMMEROA","dateModified":"2023-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0D40F4A4-F20D-DA31-E050-BB89AD432147","beginDate":"2015-01-22","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-01-22","modifiedBy":"ONEDATA","dateModified":"2015-01-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2240632","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F9FA7953-8391-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"ONEDATA","dateModified":"2005-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3ED757E8-43D9-0DAB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"ROUILLAS","dateModified":"2015-01-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811835","version":"1","longName":"Melanoma","context":"CTEP"},{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"2811907","version":"1","longName":"Bladder","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811949","version":"1","longName":"Brain","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"}],"ReferenceDocuments":[{"name":"Toxicities that led to the su","type":"Preferred Question Text","description":"Toxicities that led to the substitution","url":null,"context":"CTEP"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Reason for substitution","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"3ED7589D-EC9E-08BA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-11-13","modifiedBy":"ROUILLAS","dateModified":"2015-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}